Top

Published in:

01-07-2012 | Breast Oncology

Race and the Prognostic Influence of p53 in Women with Breast Cancer

Authors: Keith A. Dookeran, MBBS, FRCS(Ed), MD, MBA, James J. Dignam, PhD, Nathaniel Holloway, MD†, Karen Ferrer, MD, Marin Sekosan, MD, Worta McCaskill-Stevens, MD, Sarah Gehlert, PhD

Published in: Annals of Surgical Oncology | Issue 7/2012

Abstract

Background

Prior study suggests that p53 status behaves as an independent marker of prognosis in African American (AA) women with breast cancer. We investigate whether the influence of p53 is unique to AAs or is present in other race/ethnic groups, and how this compares with known prognostic factors.

Methods

Cox regression models [hazard ratios (HRs), 95% confidence intervals (CIs)] were used to select and evaluate factors prognostic for all-cause mortality in 331 AA and 203 non-AA consecutively treated women.

Results

Statistically significant baseline prognostic factors were as follows. For AAs: stage [(III/I) HR 5.57; 95% CI 3.08–10.09], grade [(higher/low) HR 1.55; 95% CI 1.14–2.11], estrogen receptor (ER)/progesterone receptor (PR) status [(−/+) HR 2.01; 95% CI 1.38–2.93], triple negative (ER−, PR−, HER2−) subtype [(+/−) HR 1.95; 95% CI 1.33–2.85], and p53 status [(+/−) HR 1.69; 95% CI 1.10–2.58]. For non-AAs: stage [HR 11.93; 95% CI 2.80–50.84], grade [HR 1.61; 95% CI 0.96–2.71], and ER/PR status [HR 2.13; 95% CI 1.19–3.81]. There was a differential effect of race within p53 groups (P = 0.05) and in multivariate modeling p53-positive status remained an adverse prognostic factor in AAs only [HR 1.82; 95% CI 1.04–3.17]. Compared to non-AAs, 5-year unadjusted survival was worse for AAs overall (73.4% vs. 63.6%; P = 0.032), and also for AAs with p53-positive status (80.3% vs. 54.2%; P = 0.016), but not for AAs with p53-negative disease (68.4% vs. 67.9%; P = 0.81).

Conclusions

Among women with breast cancer of different race/ethnicity, an adverse prognostic effect as a result of p53 positivity was only observed in AA women.

Dookeran KA, Dignam JJ, Ferrer K, et al. p53 as a marker of prognosis in African-American women with breast cancer. Ann Surg Oncol. 2010;17:1398–405.PubMedCrossRef

Commission on Cancer of the American College of Surgeons. Cancer Program Standards 2004. http://www.facs.org/cancer/coc/cocprogramstandards.pdf. Accessed 25 Sep 2008.

U.S. Census Bureau. Poverty, 1999. Census 2000 brief. http://www.census.gov/prod/2003pubs/c2kbr-19.pdf. Accessed 14 Dec 2010.

Tehranifar P, Neugut AI, Phelan JC, et al. Medical advances and racial/ethnic disparities in cancer survival. Cancer Epidemiol Biomarkers Prev. 2009;18:2701.PubMed

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–10.PubMedCrossRef

Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC; 2003.

Fleming ID, Cooper JS, Hensen DE, ed. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven; 1997.

Greene FL, Page DL, Fleming ID, ed. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.

Porter PL, Lund MJ, Lin MG, et al. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer. 2004;100:2533–42.PubMedCrossRef

10.

Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.PubMedCrossRef

11.

Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994;86:705–12.PubMedCrossRef

12.

Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–68.PubMed

13.

Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York: Springer; 2003.

14.

Baker L, Quinlan PR, Patten N, et al. p53 mutation, deprivation and poor prognosis in primary breast cancer. Br J Cancer. 2010;102:719–26.PubMedCrossRef

15.

Jones BA, Kasl SV, Howe CL, et al. African-American/white differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer. 2004;101:1293–301.PubMedCrossRef

16.

Dookeran KA, Gao X, Ferrer K, et al. Evaluation of p53 immunoreactivity in African-American patients with breast cancer. Proceedings of the American Association for Cancer Research (94th Annual Meeting, July 11–14 2003, Washington, DC). 2003;44:295.

17.

Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients. Cancer. 2007;110:876–84.PubMedCrossRef

18.

Lai H, Lai S, Ma F, Meng L, Trapido E. Prevalence and spectrum of p53 mutations in white Hispanic and non-Hispanic women with breast cancer. Breast Cancer Res Treat. 2003;81:53–60.PubMedCrossRef

19.

Greenberg S, Rugo HS. Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer. Clin Breast Cancer. 2010;10:20–9.CrossRef

20.

Millar EKA, Graham PH, O’Toole SA, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 2009;27:4701–8.PubMedCrossRef

21.

Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 2008;26:1–10.PubMedCrossRef

22.

Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684–91.PubMedCrossRef

23.

Komenaka IK, Martinez ME, Pennington RE, et al. Race and ethnicity and breast cancer outcomes in an underinsured population. J Natl Cancer Inst. 2010;102:1178.PubMedCrossRef

24.

Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA. Health disparities in breast cancer: biology meets socioeconomic status. Breast Cancer Res Treat. 2010;121:281–92.PubMedCrossRef

25.

DeNavas-Walt C, Proctor BD, Lee CH. Income, poverty, and health insurance coverage in the United States: 2005. In: U.S. Census Bureau. Current population reports. Washington: U.S. Government Printing Office; 2006. p. 60–231.

26.

Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–502.PubMedCrossRef

27.

Dookeran K, Gao X, Wang Y, et al. Basal subtype predicts poorer prognosis in younger, but not older, African-American women with breast cancer. AACR meeting abstracts, No. 2510. 14 Apr 2007.

28.

Cheang MCU, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368.PubMedCrossRef

29.

Lund MJ, Butler EN, Hair BY, et al. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes. Cancer. 2010;116:2549–59.PubMed

30.

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109:1721–8.PubMedCrossRef

31.

Carstairs V, Morris R. Deprivation and health in Scotland. Aberdeen: Aberdeen University Press; 1991.

32.

Oliveira AM, Fletcher JA, Ross JS. Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Pathol Patterns Rev. 2005;124:16–28.CrossRef

33.

Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85:200–6.PubMedCrossRef

34.

Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L, Coplete J. Sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1995;1:1029–34.PubMedCrossRef

35.

Harris LN, Broadwater G, Lin NU, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006;8(6):R66.PubMedCrossRef

36.

Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000;6:50–6.PubMed

37.

Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992;84:845–55.PubMedCrossRef

38.

Dookeran KA, Gao X, Wang Y, et al. p53 gene mutations in African-American women with breast cancer. Breast Cancer Res Treat. 2006;100(Suppl. 1):S145.

39.

Blaszyk H, Vaughn CB, Hartmann A, et al. Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. Lancet. 1994;343(8907):1195–7.PubMedCrossRef

40.

Shiao YH, Chen VW, Scheer WD, Wu XC, Correa P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res. 1995;55:1485–90.PubMed

41.

Shiao YH, Chen VW, Wu XC, et al. Racial comparison of p53 alterations in breast cancer: difference in prognostic value. In Vivo. 1996;10:169–73.PubMed

Title: Race and the Prognostic Influence of p53 in Women with Breast Cancer
Authors: Keith A. Dookeran, MBBS, FRCS(Ed), MD, MBA
James J. Dignam, PhD
Nathaniel Holloway, MD†
Karen Ferrer, MD
Marin Sekosan, MD
Worta McCaskill-Stevens, MD
Sarah Gehlert, PhD
Publication date: 01-07-2012
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 7/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-011-1934-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Race and the Prognostic Influence of p53 in Women with Breast Cancer

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2012

Erratum to: A Phase I Trial of Oxaliplatin for Intraperitoneal Hyperthermic Chemoperfusion for the Treatment of Peritoneal Surface Dissemination from Colorectal and Appendiceal Cancers

Comparison Between Radical Esophagectomy and Definitive Chemoradiotherapy in Patients with Clinical T1bN0M0 Esophageal Cancer

Putatively Functional PLCE1 Variants and Susceptibility to Esophageal Squamous Cell Carcinoma (ESCC): A Case–Control Study in Eastern Chinese Populations

Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or Gemcitabine Followed by Chemoradiation in Pancreatic Cancer: A Randomized Phase II Trial

Diagnostic Accuracy of MRI for Assessment of T Category, Lymph Node Metastases, and Circumferential Resection Margin Involvement in Patients with Rectal Cancer: A Systematic Review and Meta-analysis

Management of the Neck in the Setting of Definitive Chemoradiation: Is There a Consensus? A GETTEC Study